Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs

Metabolic Disturbance Clinical Trial

— PAH-ProMetGen  

Official title:

Biological Signatures (Proteomics, Metabolomics and Genotoxicity) Associated With Occupational Exposure to PAH Mixtures and Relation With Exposure Biomarkers: Support for the Derivation of Biological Limit Values

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05679544
• Other study ID #: 38RC22.0219
• Secondary ID: 2022-A01590-43
• Status: Recruiting
• Phase: N/A
• Start date: April 25, 2023
• Est. completion date: October 2025

Study information

• Verified date: May 2024
• Source: University Hospital, Grenoble
• Contact: Renaud PERSOONS, PhD, Pharm D
• Phone: 00 33 4 76 76 51 78
• Email: RPersoons[@]chu-grenoble.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research project aims at better understanding the early biological effects resulting from occupational exposure to complex Polycyclic Aromatic Hydrocarbon (PAH) mixtures.

Current biomarkers used as part of biomonitoring campaigns are biomarkers of exposure, not numerous and poorly related to health effects.

The aim of this study is thus to improve our understanding of biological consequences of such exposures, both in terms of proteins deregulation, metabolism deregulation and genotoxicity.

Description:

PAHs are ubiquitous pollutants inducing several diseases, among which cancer is the most significant endpoint, with increased incidences of lung, skin, and bladder cancers. PAHs induce genotoxic effects (sister chromatids exchange, micronuclei, DNA damage) but require metabolic activation in humans as indirect-acting carcinogens. Thus, the knowledge of metabolic pathways involved following PAH exposure is critical for understanding and preventing cancer risks. Besides, exposure to PAHs is assumed to induce other adverse health effects (diabetes, inflammation, infertility, cardiovascular disease). Unfortunately, early disease-related biomarkers are still largely unknown and our comprehension about the mechanisms involved is still limited. The rare existing biological limit values either refer to not carcinogenic PAH (pyrene) or detoxification pathways (3-OHBaP for BaP), although new biomarkers reflecting the genotoxic pathway of BaP (TetraolBaP) are now available. There is thus a need for identifying more relevant biomarkers of exposure / effect, and for a better understanding of the biological consequences resulting from PAH exposures as well as the associated metabolic pathways involved.

The objectives of the project are :

• To better understand and characterize molecular, metabolic and genotoxic impacts resulting from exposure to PAHs and to link such impacts with biological levels of various PAH metabolites,

• To study the influence of BaP metabolism (genotoxic versus detoxication pathway) on the differential expression of metabolites / proteins and on genotoxicity endpoints in order to get relevant data for deriving new biological limit values,

• To elucidate the associations between omics deregulations due to PAH exposures and activated metabolic pathways, in order to define candidate effect biomarkers for human biomonitoring.

The originalities of the project are the following. First, this is a human study performed in real occupational settings on workers exposed to representative PAH mixtures. It is a multidisciplinary approach simultaneously combining up-to-date biomonitoring, omics and cytogenetics analyses, that will give insight into a comprehensive view of metabolic reactions and protein expressions following occupational exposure to PAH mixtures, and allow the identification of the biological processes involved. Carcinogenic BaP metabolites (Tetraol-BaP and 3-OHBaP) will be simultaneously analyzed in order to compare the two main metabolic pathways of BaP.

The main steps of the projects will be :

• Recruitment of 100 workers differentially exposed to PAH mixtures sampled across two time periods (after weeks of exposure and following 3 weeks without occupational exposure),

• Recording of relevant data (work characteristics, jobs / tasks, working experience, number of years of exposure, smoking habits, nutritional intake, co-morbidity),

• Toxicological analyses (LC-Fluorescence and GC-MS-MS) of urinary metabolites of several gaseous and particulate PAHs (Naphtalene, Fluorene, Phenanthrene, Pyrene, BaP, BeP, Chrysene, Benzo(b)Fluoranthene, Benzo(k)Fluoranthene, Benzo(a)Anthracene),

• Proteomics analyses on blood samples through an enrichment approach for a bottom-up label free quantitative proteomic analysis based LC-HR-MS. Deregulated proteins (DEP) will be identified and the associated protein signature. A gene ontology (GO) analysis will define the groups of biological processes involved,

• Untargeted Metabolomics analyses on blood samples in UHPLC-HR-MS, with unsupervised statistical analyses (Principal Component Analysis, Logistic Regressions), identification of relevant metabolites by their comparison to the Human Metabolome database, and advanced molecular networking / spectral library search of LC-MSMS data,

• Micronuclei (MN) in buccal cells through the harvesting of buccal cells using a cytobrush, transfer to the lab in a buffer, fixing and staining, automatic counting under fluorescent light.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: October 2025
• Est. primary completion date: October 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects ages 18 years or more

• Subjects occupationally exposed to PAHs since more than 3 months

• Having signed the informed consent

• recruited by the occupational health service

Exclusion Criteria:

• Obesity (BMI>30)

• Subjects suffering cancers or metabolic diseases (diabetes, dyslipidemia, amino-acid diseases, renal or hepatic impairment) at the onset of the study.

• Subjects taking medications related to the above diseases at the onset of the study.

Related Conditions & MeSH terms

• Genotoxicity
• Metabolic Disturbance
• Protein Deficiency

Intervention

Biological:
• Characterization of early biological effects following exposure to PAHs
Biological samples collected in period of exposure and after holidays

Locations

Country	Name	City	State
France	CHU Grenoble Alpes	Grenoble

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Deregulation of blood proteins expression due to exposure to PAHs	Number of proteins up or down regulated in period of exposure versus after holidays	up to 6 months between both periods of study
Primary	Deregulation of blood metabolites expression due to exposure to PAHs	Number of metabolites up or down regulated in period of exposure versus after holidays	up to 6 months between both periods of study
Primary	Frequency of micronuclei measured due to exposure to PAHs	Frequency of cells containing micronuclei in period of exposure versus after holidays	up to 6 months between both periods of study